Miravant results revived: Bausch & Lomb to review potential AMD drug

July 15, 2002

Santa Barbara, CA-Bausch & Lomb will review results of Miravant Medical Technologies' SnET2 trials with an option to negotiate the exclusive worldwide license to develop and commercialize the drug for the treatment of wet age-related macular degeneration (AMD).